EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Metformin Impairs Linsitinib Anti-Tumor Effect on Ovarian Cancer Cell Lines

Diana Luísa Almeida-Nunes iD, João P N Silva iD, Mariana Nunes iD, Patrícia M A Silva iD, Ricardo Silvestre, Ricardo Jorge Dinis-Oliveira iD, Hassan Bousbaa iD, Sara Ricardo iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms252211935 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Diana Luísa Almeida-Nunes und 7 weiteren Autor:innen. Beteiligte Einrichtung: Associate Laboratory i4HB-Institute for Health and Bioeconomy, University Institute of Health Sciences-CESPU, 4585-116 Gandra, Portugal. Hauptthemen laut MEDLINE: Metformin, Ovarian Neoplasms, Cell Proliferation, Apoptosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cooperativa de Ensino Superior Politécnico e Universitário, Fundação para a Ciência e Tecnologia, Fundação para a Ciência e a Tecnologia (FCT).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ovarian cancer (OC) remains one of the leading causes of cancer-related mortality among women. Targeting the insulin-like growth factor 1 (IGF-1) signaling pathway has emerged as a promising therapeutic strategy. Linsitinib, an IGF-1 receptor (IGF-1R) inhibitor, has shown potential in disrupting this pathway. Additionally, metformin, commonly used in the treatment of type 2 diabetes, has been studied for its anti-cancer properties due to its ability to inhibit metabolic pathways that intersect with IGF-1 signaling, making it a candidate for combination therapy in cancer treatments. This study explores the anti-cancer effects of linsitinib and metformin on OVCAR3 cells by the suppression of the IGF-1 signaling pathway by siRNA-mediated IGF-1 gene silencing. The goal is to evaluate their efficacy as therapeutic agents and to emphasize the critical role of this pathway in OC cell proliferation. Cellular viability was evaluated by resazurin-based assay, and apoptosis was assessed by flux cytometry. The results of this study indicate that the combination of linsitinib and metformin exhibits an antagonistic effect (obtained by SynergyFinder 2.0 Software), reducing their anti-neoplastic efficacy in OC cell lines. Statistical analyses were performed using ordinary one-way or two-way ANOVA, followed by Tukey’s or Šídák’s multiple comparison tests. While linsitinib shows promise as a therapeutic option for OC, further research is needed to identify agents that could synergize with it to enhance its therapeutic efficacy, like the combination with standard chemotherapy in OC (carboplatin and paclitaxel).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminOvarian NeoplasmsCell ProliferationApoptosisImidazolesHumansFemaleCell Line, TumorAntineoplastic AgentsPyrazinesSignal TransductionCell SurvivalReceptor, IGF Type 1Insulin-Like Growth Factor IDrug Synergism

Stichwörter der Autor:innen

IGF-1 signaling pathwayapoptosiscell viabilitylinsitinibmetforminovarian cancer

Substanzen

Metformin3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanolImidazolesAntineoplastic AgentsPyrazinesReceptor, IGF Type 1Insulin-Like Growth Factor I

Autor:innen und Institutionen

  • Associate Laboratory i4HB-Institute for Health and Bioeconomy, University Institute of Health Sciences-CESPU, 4585-116 Gandra, Portugal.
  • UCIBIO-Applied Molecular Biosciences Unit, Toxicologic Pathology Research Laboratory, University Institute of Health Sciences (1H-TOXRUN, IUCS-CESPU), 4585-116 Gandra, Portugal.
  • Differentiation and Cancer Group, Institute for Research and Innovation in Health (i3S) of the University of Porto, 4200-135 Porto, Portugal.
  • UNIPRO-Oral Pathology and Rehabilitation Research Unit, Institute of Health Sciences (IUCS), Cooperativa de Ensino Superior Politécnico e Universitário (CESPU), Rua Central de Gandra 1317, 4585-116 Gandra, Portugal.
  • School of Medicine and Biomedical Sciences (ICBAS), University of Porto, 4050-313 Porto, Portugal.
  • UCIBIO-Applied Molecular Biosciences Unit, Translational Toxicology Research Laboratory, University Institute of Health Sciences (1H-TOXRUN, IUCS-CESPU), 4585-116 Gandra, Portugal.

ORCID-Profile: Diana Luísa Almeida-Nunes, João P N Silva, Mariana Nunes, Patrícia M A Silva, Ricardo Jorge Dinis-Oliveira, Hassan Bousbaa, Sara Ricardo

Förderung

  • Cooperativa de Ensino Superior Politécnico e Universitário
  • Fundação para a Ciência e Tecnologia
  • Fundação para a Ciência e a Tecnologia (FCT)
  • CESPU—Cooperativa de Ensino Superior Politécnico e Universitário CRL
  • National funds
  • FCT contract
  • FCT/MCTES and União Europeia (UE)
  • CESPU

Zitieren

APA

Almeida-Nunes, D. L., Silva, J. P. N., Nunes, M., Silva, P. M. A., Silvestre, R., Dinis-Oliveira, R. J., Bousbaa, H., & Ricardo, S. (2024). Metformin Impairs Linsitinib Anti-Tumor Effect on Ovarian Cancer Cell Lines. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252211935

Vancouver

Almeida-Nunes DL, Silva JPN, Nunes M, Silva PMA, Silvestre R, Dinis-Oliveira RJ, et al. Metformin Impairs Linsitinib Anti-Tumor Effect on Ovarian Cancer Cell Lines. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252211935

BibTeX
@article{AlmeidaNunes2024,
  author = {Almeida-Nunes, Diana Luísa and Silva, João P N and Nunes, Mariana and Silva, Patrícia M A and Silvestre, Ricardo and Dinis-Oliveira, Ricardo Jorge and Bousbaa, Hassan and Ricardo, Sara},
  title = {Metformin Impairs Linsitinib Anti-Tumor Effect on Ovarian Cancer Cell Lines},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms252211935}
}
Kostenlos starten →